MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $20,973,750 | -32.4% | 6,375,000 | -15.6% | 0.28% | -38.0% |
| Q1 2023 | $31,030,500 | -29.9% | 7,550,000 | 0.0% | 0.46% | -30.4% |
| Q4 2022 | $44,243,000 | -13.3% | 7,550,000 | 0.0% | 0.66% | -29.9% |
| Q3 2022 | $51,038,000 | +46.3% | 7,550,000 | 0.0% | 0.94% | +36.9% |
| Q2 2022 | $34,881,000 | +28.6% | 7,550,000 | +11.0% | 0.69% | +39.2% |
| Q1 2022 | $27,132,000 | -35.9% | 6,800,000 | 0.0% | 0.50% | -31.2% |
| Q4 2021 | $42,296,000 | -34.0% | 6,800,000 | 0.0% | 0.72% | -28.5% |
| Q3 2021 | $64,124,000 | -30.6% | 6,800,000 | 0.0% | 1.01% | -37.3% |
| Q2 2021 | $92,344,000 | -16.1% | 6,800,000 | 0.0% | 1.61% | -15.5% |
| Q1 2021 | $110,024,000 | -39.2% | 6,800,000 | 0.0% | 1.90% | -39.0% |
| Q4 2020 | $180,948,000 | +42.9% | 6,800,000 | 0.0% | 3.12% | +73.2% |
| Q3 2020 | $126,616,000 | -16.8% | 6,800,000 | +4.6% | 1.80% | -40.2% |
| Q2 2020 | $152,100,000 | – | 6,500,000 | – | 3.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |